Abstracts tagged "Adalimumab and rheumatoid arthritis"

Abstract Number: 2470 • 2014 ACR/ARHP Annual Meeting
Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Adalimumab (ADA) showed highly efficacious in rheumatoid arthritis (RA) in the clinical trials, although there is little evidence in daily clinical practice.The clinical usefulness…
Abstract Number: 776 • 2012 ACR/ARHP Annual Meeting
A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission
Katerina Chatzidionysiou¹, Carl Turesson², Annika Teleman³, Ann Knight⁴, Elisabet Lindqvist⁵, Per Larsson⁶, Lars Cöster⁷, Barbro Rydberg⁸, Ronald F. van Vollenhoven⁹ and Mikael Heimbürger¹⁰, ¹Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, ⁴Dept of Rheumatology, Institution for Medical Sciences, Uppsala University, Uppsala, Sweden, ⁵Department of Clinical Sciences, Section for Rheumatology Lund University, Lund, Sweden, ⁶Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁷Department of Rheumatology, University Hospital, Linköping, Sweden, ⁸Department of Rheumatology, Kärnsjukhuset, Skövde, Sweden, ⁹Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ¹⁰Medical department, Abbott Scandinavia, Stockholm, Sweden
Background/Purpose: Treatment with TNF blockers, once started as therapy for RA, is usually continued indefinitely. Information about the possibility to discontinue anti-TNF therapy in RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].